tirzepatide off label is a novel medication that the FDA has approved for treating type 2 diabetes mellitus. Due to its potent weight loss properties, Tirzepatide can be used off-label for treating obesity. The FDA approves Eli Lilly's diabetes

Even if studies do not query subjects for heartburn and reflux and most dont all GI GLP-1 side-effects lead to acid reflux, both esophageal reflux and respiratory reflux

Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis

Ocular migraines: Potentially triggered by stress, hormonal changes, or medications affecting blood vessels, Rybelsus patients may experience migraines involving visual disturbances such as flashing lights, zigzag patterns, or temporary vision loss

These findings highlight the potential for Semaglutide to offer protective cardiovascular effects, which is particularly important for patients with type 2 diabetes who are at higher risk for cardiovascular diseases